Tweets
Greater #comorbidity burden is assoc. w/ worse improvement and disease activity in 1st yr of treatment in ERA @earlyarthritis.
Comorbidities esp affect SJC and patient and physician global assessments.
#ACR21 Abs#0798 @RheumNow
https://t.co/02BRqYp9Yk
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 8 months ago
#ACR21 Abst#0801 Early remission at 6 mos is a predictor of long-term remission in patients w new onset RA
▶️ DAS28-CRP, SDAI, CDAI at 6mo predicted remission at 60 months
https://t.co/vWy7EmseZp @Rheumnow https://t.co/HWJSjvFY8d
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
Good news for #COVID vaccine in #SLE. ✅doesn’t cause #lupus flares ➡️ no increase in APS. What about #SARS-CoV2 infection in SLE. Flares ↔️ stable but ⬆️APS Abs. from Hopkins cohort. Petri #ACRBest #ACR21 abst0858 @RheumNow https://t.co/ABx4C4lwvs
Janet Pope @Janetbirdope ( View Tweet )
4 years 8 months ago
How can we better identify patients with #RA-ILD using #EHRs?
Abs#0561: previously validated algorithms have clinical & research utility when applied to EHRs, esp when well-integrated with key info such as CT chest reports
#ACR21 @RheumNow
https://t.co/OU8BdwqHpc
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 8 months ago
ADACTA & MONARCH both showed IL6i monoRx > TNFi monoRx for RA in DBRCTs.
What about in real-world data?
Looking at CorEvitas, less so
LDA: aOR 0.99
MCID in CDAI: 1.06
Even without MTX, both great drug classes for RA
Equally so?
#ACR21 ABST0834 @RheumNow https://t.co/6wvzVrXTW6 https://t.co/fYEktJhZuV
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
#ACR21 A#0563 - Is FRAX score applicable for RA? 10 yr Olmsted County epi study: Yes
▶️ 76 osteoporotic fxs in RA pts, FRAX predicted 67 fx (SIR 1.13, not signif)
▶️ 21 observed hip fx, FRAX predicted 23.3 (SIR 0.9)
⭐️ No differences by ages/sex
https://t.co/vWy7EmseZp @Rheumnow https://t.co/8BlzgQYqaV
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
6 year f/up study of sacroilitis in nr-AxSpA pts
⭐️~10% of pts progressed from nr-AxSpa to AS every 2 years
Abs#907
#ACR21
@RheumNow
https://t.co/kiWGmKhpWu
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 8 months ago
Watch: What I'm Looking Forward to at #ACR21: Dr. Arthur Kavanaugh
https://t.co/WygW1czwXn https://t.co/1qlZsFBd4Z
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Guidance on self-efficacy (SE) in IA were published this yr- what factors influence this?
👉PROMs & treatment response determine long-term SE
👉This may help identify pts benefitting most from interventions to improve SE
Abs#0795 #ACR21 @RheumNow
https://t.co/dx28WgxNsE https://t.co/7uN6XctnQb
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 8 months ago
#ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX:
▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX.
⭐️Age, sex, waist circumference, BMI are risks
@Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
In Australia, there's free choice of originator vs biosimilar for etanercept.
Real-world data shows exactly what you'd expect over >48 months - and sometimes it's what you expect that's exactly what you want to see...
OPAL data #ACR21 0840 @RheumNow https://t.co/YJA2Cua9cw
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
It was a pleasure to speak to Dr Bryant England about #multimorbidity in #rheumatoidarthritis with a focus on abstract #1924, to be presented at the #Epidemiology & #PublicHealth abstract session on Tuesday #ACR21: https://t.co/qHws6B3fFf
Watch @RheumNow: https://t.co/OKM7WxIEpR
Links:
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 8 months ago
